Clinical trial · Interventional
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours
NCT00750841CI-TRIAL-00122220active not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cediranib | Drug | Cediranib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
- interventionNames
- Drug: cediranib
Primary outcomes (1)
- measure
- To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin
- timeFrame
- PK assessments to be taken until Day 28. Days 7 and 14 PK parameters used to assess the primary variables.
Secondary outcomes (1)
- measure
- To assess the safety and tolerability of cediranib in the presence of rifampicin, by assessment of Adverse events (AEs) Laboratory findings, Vital signs, physical examination and Electrocardiogram.
- timeFrame
- Until study drug is discountinued
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 130 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent * Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists. * Estimated life expectancy of at least 8 weeks * WHO performance status (PS) 0-2. Exclusion Criteria: * Unstable brain/meningeal metastases * Biochemistry/haematology results outside of required ranges * History of significant GI impairment * Inadequate bone marrow reserve
References
Publications (0)
Data not yet available
No reference posted for this study.